Skip to main content

Pearce and Frye Become Co-Directors

Of the Center for Integrative Chemical Biology and Drug Discovery

 

FromKen Pearce Angela Kashuba, Dean UNC Eshelman School of Pharmacy:

I am delighted to announce that Ken Pearce, Ph.D., will become co-director of the Center for Integrative Chemical Biology and Drug Discovery on March 1.

Ken brings a wealth of experience in biochemistry, biophysics and assay development to this position. Stephen Frye, Ph.D., will remain as co-director with Ken for a three-year period before transitioning full time to his faculty position. After serving as co-director for three years, Ken will move into the fulltime director role.

As co-director, Ken will continue to expand the Center for Integrative Chemical Biology and Drug Discovery as a premier academic center that is focused on translating UNC biomedical science into the discovery of small molecule medicines and chemical research tools. The Center will maintain a focus on cancer relevant drug discovery and chemical biology research while expanding into new collaborative areas identified as important for the campus, including neuroscience and infectious diseases.

Please join me in congratulating Ken on this new leadership position.

All the best,

Angela

ANGELA DM KASHUBA, BScPhm, PharmD, DABCP, FCP
Dean, UNC Eshelman School of Pharmacy
John A. and Margaret P. McNeill, Sr. Distinguished Professor
Director, Clinical Pharmacology and Analytical Chemistry Core, UNC Center for AIDS Research
Adjunct Professor of Medicine, UNC School of Medicine, Division of Infectious Diseases

esop_dean@unc.edu | 919-966-1122

UNC ESHELMAN SCHOOL OF PHARMACY

Campus Box 7355

100C Beard Hall | 301 Pharmacy Lane

Chapel Hill, NC 27599-7355

pharmacy.unc.edu

 


Combining accomplished pharmaceutical scientists and cutting edge academicians focused on oncology drug discovery and the chemical and structural biology of chromatin regulation. The first clinical candidate from the Center is advancing through Pipettingclinical trials and is a targeted therapeutic designed to reactivate the innate immune response in cancer and block survival signaling pathways in many solid and hematologic malignancies. The Center’s chromatin science is centered on methyl-lysine as a posttranslational modification and the protein-protein interactions that it facilitates.  The first chemical probes for methyl-lysine reader proteins were discovered in the CICBDD and are being used to validate novel interventions in cancer and other diseases.